• mssVIM–IGF-1R Signaling in Cancer Metastasis

  2026-08-28

  This bioRxiv preprint identifies a macrophage-secreted, N-terminally truncated vimentin variant that promotes breast cancer cell migration through an IGF-1R–RSK–integrin αVβ6 axis. The work reframes vimentin processing as a tumor-microenvironment signaling event and provides a mechanistic basis for associating mssVIM with malignancy and lymph-node metastasis, while requiring further peer-reviewed validation.

• Intravesical p21 mRNA–LNPs for Bladder Cancer

  2026-08-27

  The reference study develops chemically modified p21 mRNA packaged in lipid nanoparticles for catheter-based intravesical treatment of bladder cancer. Its data show localized p21 restoration, suppression of tumor-cell proliferation, and reduced tumor growth in an orthotopic mouse model, while also defining important translational questions about dosing, formulation, and clinical delivery.

• Dihydroartemisinin Research Workflows

  2026-08-27

  Build more reproducible malaria, mTOR, and inflammation assays with a defined Artemisia-derived compound rather than a chemically variable extract. This guide covers stock preparation, washout designs, pathway readouts, comparative controls, and troubleshooting for Dihydroartemisinin research.

• Triptolide (PG490): Transcription Meets Translation

  2026-08-26

  Triptolide (PG490) is more than a potent transcriptional inhibitor: it is a translational probe for studying how transcriptional stress, immune signaling, invasion, apoptosis, and genome stability intersect. This article connects triptolide’s CDK7–RNAPII activity with new findings on cell-cycle-controlled transcription condensates, then translates those insights into experimental design, biomarker selection, and preclinical decision-making.

• BMS-777607: MET Signaling and Assay Design

  2026-08-26

  BMS-777607 is a selective c-Met inhibitor for dissecting MET signaling, tumor metastasis, and exploratory megakaryocyte assays. This article connects its kinase pharmacology with a 2026 hiPSC-derived platelet study while separating validated findings from hypothesis-generating applications.

• TRIM21–ERK1/2 in Pituitary Tumor Resistance

  2026-08-25

  The reference study identifies TRIM21 as a context-dependent regulator of ERK1/2 signaling, pituitary adenoma proliferation, and dopamine-agonist resistance. Its combination of CRISPR screening, interaction proteomics, ubiquitination analysis, and drug screening nominates TRIM21 suppression—and compounds including Quisinostat—as a testable therapeutic strategy.

• Phosbind Acrylamide: From Shift to Mechanism

  2026-08-25

  Phosbind Acrylamide converts phosphorylation-dependent mobility changes into a practical mechanistic readout for protein phosphorylation analysis. This article connects phosphate-affinity SDS-PAGE with the SmCPK20–SmWRKY2 jasmonate pathway and explains how to design, control, and interpret the assay.

• Molidustat (BAY85-3934) HIF Study Workflow

  2026-08-24

  Molidustat (BAY85-3934) gives researchers a practical way to connect HIF stabilization with erythropoietin stimulation, renal anemia therapy, and hypoxic-cell assays. This workflow also uses a cardiomyocyte injury model to test whether pharmacologic HIF preservation can offset VHL-associated HIF-1α loss, while clearly separating established findings from exploratory applications.

• BPN-19186: Reliable Cell Assay Workflows

  2026-08-23

  A practical, evidence-aware guide to using SKU A8959, also known as BPN-19186, in cell viability, proliferation, cytotoxicity, and pathway-focused experiments. It connects compound handling and controls with recent sEH–Nrf2–osteoclastogenesis findings while clearly separating established data from workflow recommendations.

• From EGFR Signaling to S-Phase Evidence

  2026-08-22

  A thought-leadership guide to connecting EGFR pathway biology with direct S-phase DNA synthesis measurement. It explains how EdU Imaging Kits (Cy5) can strengthen mechanism-of-action studies, pharmacodynamic decisions, genotoxicity assessment, and translational assay strategy.

• FBXO22 Degraders and 2-PCA Recruitment Ligands

  2026-08-21

  This preprint expands targeted protein degradation by developing chemical tools for the cancer-associated E3 ligase FBXO22. It reports a selective FBXO22 degrader, defines a chain-length requirement for diamine-mediated self-degradation, and introduces 2-pyridinecarboxaldehyde as a reversible electrophilic recruitment ligand capable of directing degradation of BRD4 and CDK12.

• Cytochalasin D for Actin Uptake Assays

  2026-08-21

  Cytochalasin D provides a focused way to test whether actin-dependent internalization contributes to nanoparticle uptake in human corneal epithelial cells. This workflow combines pathway perturbation with viability, morphology, particle-quality, and surface-binding controls so reduced fluorescence is not mistaken for reduced entry.

• Superoxide Dismutase Activity Assay Kit Guide

  2026-08-20

  The Superoxide Dismutase Activity Assay Kit provides a colorimetric way to quantify SOD activity in biological fluids by measuring inhibition of WST-1 reduction at 450 nm. It is intended for controlled research workflows, including oxidative stress studies, and should not be used for diagnosis, patient testing, or therapeutic decisions.

• (R)-MG132 in Causal Cancer Metabolism Assays

  2026-08-20

  (R)-MG132 is an inactive MG-132 enantiomer that helps separate proteasome-dependent effects from nonspecific cellular responses. This guide develops an assay strategy for applying the stereoisomeric control to studies of HNRNPU lactylation, PHGDH, and cervical cancer metabolism.

• Chloroquine BA1002: Mechanisms and Research Use

  2026-08-19

  Chloroquine is a 4-aminoquinoline research compound that raises lysosomal pH, inhibits late-stage autophagic flux, and modulates inflammatory and survival pathways. BA1002 is suited to malaria, rheumatoid arthritis, autophagy, Toll-like receptor, antiviral, and cancer research, but in-vitro activity and research concentrations do not establish clinical efficacy or dosing.

443 records 6/30 page Previous Next First page 上5页 678910 下5页 Last page